INSPIRE: Integrating Circulating DNA Methylation and Fragmentomics to Scan and Pinpoint Cancer Signals Effectively

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

This research constitutes a multi-centric, case-control designed investigation aimed at developing and implementing a blinded validation of a machine learning-powered, multi-cancer early detection model. This is to be achieved through the prospective collection of blood specimens from newly diagnosed cancer patients and individuals devoid of a confirmed cancer diagnosis

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 75
Healthy Volunteers: f
View:

• 40-75 years old

• Clinically and/or pathologically diagnosed cancer

• No prior or undergoing any systemic or local antitumor therapy, including but not limited to surgical resection, radiochemotherapy, endocrinotherapy, targeted therapy, immunotherapy, interventional therapy, etc.

• Able to provide a written informed consent and willing to comply with all part of the protocol procedures

• 40-75 years old

• Without confirmed cancer diagnosis

• Able to provide a written informed consent and willing to comply with all part of the protocol procedures

Locations
Other Locations
China
Fudan University
RECRUITING
Shanghai
Contact Information
Primary
Zhixi Su, PHD
zhixi.su@singlera.com
+862180113170
Backup
Rui Liu
rliu@singlera.com
+862180113170
Time Frame
Start Date: 2024-07-20
Estimated Completion Date: 2025-02-28
Participants
Target number of participants: 5350
Treatments
Case arm
Participants newly diagnosed with cancer, belonging to one of thirteen distinct cancer types.
Control arm
Healthy or benign condition participants with no cancer diagnosis subsequent to routine cancer screening tests.
Sponsors
Collaborators: Anhui Provincial Hospital, China-Japan Friendship Hospital, Hubei Cancer Hospital, Huazhong University of Science and Technology, Shanghai Electric Power Hospital, The First Affiliated Hospital of Xi' an Jiaotong University, Beijing Friendship Hospital, Fudan University, East Hospital, Tongji University, GaoZhou People's Hosipital, Shaanxi Provincial Cancer Hospital, Xuhui Central Hospital, Fudan University
Leads: Singlera Genomics Inc.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials